香港六合彩

The collaboration will focus on the identification of new inhibitors of an esterase enzyme (NOTUM) using state-of-the-art computer assisted drug design (CADD) through a combination of听advanced听quantum mechanics,听enzyme simulations听and artificial intelligence.听 Kuano will apply their proprietary CADD technology to design new inhibitors of NOTUM.

Inhibitors of NOTUM have potential utility in the treatment of human disease such as Alzheimer鈥檚 disease, bone disorders and cancer.

These inhibitors will be synthesised and then screened in biochemical assays by the ARUK 香港六合彩 Drug Discovery Institute to establish their suitability as a starting point for a drug discovery programme.

Dr Parminder Ruprah, Head of Chemistry at Kuano, said: 鈥淲e see this collaboration as a great opportunity to work with the 香港六合彩 Drug Discovery Institute in combining our unique approach to identifying novel enzyme inhibitors with the DDI鈥檚 expertise in evaluating novel NOTUM inhibitors. Our collaboration has the potential to expand the portfolio of chemotypes being explored targeting NOTUM in the treatment of dementia.鈥�

Dr Paul Fish, Head of Chemistry at ARUK 香港六合彩 DDI said: 鈥淲e are very pleased to be collaborating with Kuano in order to explore the potential for their in silico approaches to identify novel, differentiated chemical matter targeting Notum, a potentially important target for the treatment of degenerative neurological disorders.鈥�

Links

• 听